What this trial studies
The purpose of this study is to better understand what types of transitions people with pancreatic cancer face when they receive chemotherapy. Again, this study defines transition as a change in a life situation or a status that causes a change in a person's identity, role, behavior, or personal relationships. Examples of transitions include changes in sleeping habits, anxiety, employment, relationship with a higher power, and treatment goals.
Conditions in scope
- Pancreatic Cancer
Interventions
- Measurement of Transitions in Cancer Scale (MOT-CA) Survey (Behavioral) — These surveys will take 5-10 minutes to complete at two time-points, T0 (baseline) and T1 (four to six weeks after baseline visit) The patient will again complete the DT and MOT-CA at a chemotherapy treatment or clinic visit, if possible,…
- Distress Thermometer Survey (Behavioral) — These surveys will take 5-10 minutes to complete at two time-points, T0 (baseline) and T1 (four to six weeks after baseline visit).The patient will again complete the DT and MOT-CA at a chemotherapy treatment or clinic visit, if possible, or…
Who can join
All sexes · Ages 18 Years and up
Inclusion criteria
- adult patients 18 years of age and older
- primary language listed as English in electronic medical record
- biopsy proven diagnosis of pancreatic cancer
- within three months after initiating a chemotherapy regimen at the Rockefeller Outpatient Pavilion at MSKCC (patient may have previously received chemotherapy at an outside institution or may have received previous chemotherapy regimens at MSKCC).
Exclusion criteria
- previous history of cancer within the past five years, except for non-melanoma skin cancer, ductal carcinoma in situ breast cancer, and thyroid cancer.
Eligibility wording paraphrased from the public record. View the full criteria on ClinicalTrials.gov before contacting a site.
Where it’s happening
| City | State / Region | Facility | Site status |
|---|---|---|---|
| New York | New York | Memorial Sloan Kettering Cancer Center (All Protocol Activities) | Unknown |
Status & timeline
- Overall status: Active, not recruiting
- Study type: Observational
- Phase: N/A
- Start date: 2020-06-05
- Primary completion: 2026-06-05
- Last update posted: 2025-07-24
- First posted: 2020-06-11
Sponsor & contact
Lead sponsor: Memorial Sloan Kettering Cancer Center (Other)
Collaborators: Hunter College School of Nursing
For trial site contact information, use the official record at ClinicalTrials.gov. Contact details change frequently and the public record is the source of truth.
Outcome measures
Primary outcomes
- Extent of the change experienced by patients with pancreatic cancer (4 to 6 weeks after baseline)
Descriptive statistics will be calculated at both time points using (part A on the MOT-CA) for each of the seven transition domains (physical, emotional, social, spiritual, cancer status, treatment, and approach) at both time points (Time 0 and Time 1).
Related ClearedRx care
If you’re reading this trial because you have menopause symptoms now, you don’t have to wait for a trial to access evidence-based care. ClearedRx prescribes the same FDA-approved and compounded HRT products that have been studied in trials like this one for decades.
Important. Information from ClinicalTrials.gov as of May 8, 2026. Trial details (status, sites, contacts, eligibility, outcomes) change frequently — always check the official record at https://clinicaltrials.gov/study/NCT04427761 before contacting a site.
ClearedRx is not affiliated with this trial or its sponsor. We index public-domain ClinicalTrials.gov records to help patients find evidence-based context for menopause care decisions. ClearedRx itself is a telehealth menopause/HRT brand — we do not enroll patients in trials.